Paradoxical Associations of Diabetes and Obesity with Abdominal Aortic Aneurysm

Publications

Share / Export Citation / Email / Print / Text size:

North American Journal of Medicine and Science

American Chinese Medical Exchange Society

Acmes Publications Inc

Subject: Medicine

GET ALERTS

ISSN: 1946-9357
eISSN: 2156-2342

DESCRIPTION

24
Reader(s)
27
Visit(s)
0
Comment(s)
0
Share(s)

VOLUME 10 , ISSUE 2 (April 2017) > List of articles

Paradoxical Associations of Diabetes and Obesity with Abdominal Aortic Aneurysm

Lu Wang * / Xi Zhang / Yiqing Song

Keywords : abdominal aortic aneurysm (AAA), diabetes, obesity

Citation Information : North American Journal of Medicine and Science. VOLUME 10 , ISSUE 2 , ISSN (Online) 2156-2342, DOI: 10.7156/najms.2017.1002083, April 2017 © 2017.

License : (Transfer of Copyright)

Received Date : 06-April-2017 / Accepted: 23-April-2017 / Published Online: 25-May-2017

ARTICLE

ABSTRACT

Abdominal aortic aneurysm (AAA), defined as a localized dilatation of abdominal aorta, is a significant cause of morbidity and mortality in aging populations. AAA is a life-threatening disease mainly because of the high fatality rates associated with aneurysm rupture. Early detection of AAAs will provide patients an opportunity to receive medical therapy and undergo elective repair before aneurysm rupture. Historically, AAA is considered a macrovascular atherosclerotic disease. Classic risk factors of atherosclerosis, such as advanced age, male gender, smoking, hyperlipidemia, and hypertension, have been associated with an increased risk of AAA formation and expansion. However, more recent laboratory and epidemiologic studies have challenged this conventional theory and indicate that the etiology of AAA is distinct from atherosclerosis per se. This review focused on the evidence on the seemingly paradoxical inverse and positive associations of diabetes and obesity, respectively, with AAA. AAA progresses more slowly in diabetics and diabetic patients are less likely to have a ruptured AAA at the time of repair, suggesting that diabetes or its medications may protect against the development and improve the prognosis of AAA. Meanwhile, obesity has been implicated in the pathogenesis of both diabetes and atherosclerosis, for which the key mechanisms include insulin resistance and release of adipokines. Data on the associations between measures of obesity and AAA are inconsistent. Insights into the relation between diabetes, obesity and AAA will help identify high-risk subpopulations for AAA screening and optimize prevention strategy for individual patients. An improved knowledge of the mechanisms underlying the link between diabetes, obesity and AAA also has important therapeutic implications.

Graphical ABSTRACT

Introduction

Abdominal aortic aneurysm (AAA), defined as a localized dilatation of abdominal aorta, is a significant cause of morbidity and mortality in aging populations. The prevalence of AAA estimated from ultrasound screening in adults aged ≥ 65 years ranged from 1.7% to 12.9% among men1-6 and from 0.6% to 1.7% among women4,5,7 in western countries. AAA is a life-threatening disease mainly because of the high fatality rates associated with aneurysm rupture. Mortality of ruptured AAA is as high as 70% for patients reaching the hospital and 35% for those undergoing emergency surgery.8,9 Early detection of AAAs will provide patients an opportunity to receive medical therapy and undergo elective repair before aneurysm rupture. Though typically silent for years, as many as 1 in 3 AAAs may eventually rupture if left undetected and untreated.10 In the US, AAA is a top 15 leading cause of death among adults aged 60-89 years.11 At least 14,000 deaths per year in the US are due to AAAs.11 This number is likely an underestimation, because rupture is usually the first and only clinical manifestation of AAA;12 an estimated 5% of the 200,000 people who died of sudden death each year may have AAA as the cause.13 Thirty-day mortality after elective open repair for AAA ranges from 3.0%14 to 8.4%;15 short-term morbidity and mortality after endovascular repair is even lower.16 Given these facts, AAA is a significant life-threatening disease that requires greater recognition and attention.

Historically, AAA is considered a macrovascular atherosclerotic disease. Classic risk factors of atherosclerosis, such as advanced age, male gender, smoking, hyperlipidemia, and hypertension, have been associated with an increased risk of AAA formation and expansion.17 However, more recent laboratory and epidemiologic studies have challenged this conventional theory and indicate that the etiology of AAA is distinct from atherosclerosis per se. The United States Preventive Services Task Force (USPSTF) recommends AAA screening for men aged 65 to 75 years with a history of smoking based on the high prevalence of AAA in smokers.18 However, these guidelines exclude other important high-risk subpopulations. More studies are critically needed to further improve AAA risk prediction. To our knowledge, only the Honolulu Heart Program,19 Health Professionals Follow-up Study,20 and Women’s Health Initiative21 have prospectively examined and reported results on risk factors for incident AAA in US adults. Most other US cohort studies either did not collect information on incident AAA, or have not explored AAA as an endpoint of interest.

Association Between Diabetes and AAA

Diabetes and atherosclerotic disease share several important pathogenic mechanisms. Diabetic patients have significantly higher risk of atherosclerotic disease in many vascular beds (including renal vasculature, carotid artery, and coronary artery). In turn, it is reasonable to postulate diabetes a potential risk factor for AAA. However, a number of large-scale screening1,6,22-27 and Clinical20,21,28-31 studies reported that the prevalence of AAA was lower in participants with versus without diabetes. Majority of previous studies that have examined associations of diabetes4,22,25,26,32,33 with AAA are cross-sectional, from which cause and effect cannot be inferred. Only a few prospective studies have examined the association between history of diabetes with incident AAA, the results are inconsistent. We are aware of 6 studies that examined the prospective associations of diabetes or impaired glucose tolerance (IGT) with incident AAA, of which one21 reported a statistically significant inverse association for diabetes, two20,30 found an inverse association for diabetes that were not statistically significant, and three19,34,35 found no association for IGT or blood glucose. The inverse association of diabetes and AAA contradicts what is expected. One possible explanation is competing risk, i.e. AAA may be particularly lethal in diabetic patients, and thus fewer patients are observed with both conditions. However, hospital data have shown that diabetics were less likely to have a ruptured AAA at the time of repair.36 AAA is also reported to progress more slowly in diabetics.37-42 These findings suggest that the observed association may represent a true protective effect of diabetes, its medications, or both, on the development and growth of AAA. We recently conducted a prospective analysis among 25,554 male physicians in the Physicians’ Health Study who were aged ≥ 50 years and reported no AAA at baseline. In this study, we documented 471 newly diagnosed AAA during a mean of 10.4 years’ follow-up. Overall, baseline history of diabetes tended to be associated with a lower risk of diagnosed AAA (hazard ratio [HR]: 0.79, 95% CI: 0.57–1.11); this association appeared to vary by follow-up time (HR = 1.56 and 0.63 during ≤ and >2 years’ follow-up, respectively). One plausible explanation is that lifestyle changes after diabetes diagnosis, such as smoking cessation, weight control and exercise, and medication treatment for diabetes may have favorable effects against AAA development and lead to a lower risk during longer-term follow-up.

Laboratory studies have suggested that diabetes may modify the risk of AAA through multiple mechanisms (Figure 1). The hyperglycemia-induced advanced glycation induces cross-linking of elastin and collagen in the extracellular matrix (ECM) within abdominal aorta wall.43 This alteration in ECM composition inhibits secretion of metaloproteinases (MMPs) in local vascular bed and prevents excessive proteolysis, a process that plays key role in formation and progression of AAA.39 Hyperglycemia also modulates expression of plasminogen activator inhibitor-1 (PAI-1) and subsequently suppresses activity of plasmin.44 These changes in fibrinolytic system potentially reduce clot degradation and renewal of intraluminal thrombus in AAA, improving aneurysmal wall stability and slowing the rate of expansion.45,46 Exposure to glycated and cross-linked collagen lattices also alter inflammation, another major factor that plays an important role in AAA.47 In diabetic aorta, cellular response of inflammatory cells change, resulting in localization of inflammation to the intima and protecting the media from matrix degradation.48 Moreover, a high aortic wall stress is fundamental to AAA development and progression.49 Diabetics have a thicker abdominal aortic wall due to increased matrix volume39,50 and therefore lower aortic wall stress.51 Finally, several drugs used in diabetes management may benefit AAA, including statins,52 angiotensin converting enzyme (ACE) inhibitors,53 metformin,54 and rosiglitazone.55 However, experimental studies showed that hyperglycemia limited AAA enlargement in mouse models, and this effect was diminished by insulin therapy.56 In clinical studies, an inverse association between fasting glucose and aortic diameter was found in non-diabetic participants.6 These findings suggest that hyperglycemia, rather than its treatment, protects against AAA development and progression.

Figure 1.

Potential effects of diabetes on pathogenesis of abdominal aortic aneurysms.

10.7156_najms.2017.1002083-f001.jpg

Association Between Obesity and AAA

Obesity, a major public health problem in the US57 and worldwide,58 is a known risk factor for many chronic diseases including diabetes and atherosclerosis. One primary mechanism by which obesity is implicated in both morbidities is insulin resistance. Findings of an inverse association between diabetes, characterized by insulin resistance, and AAA raise further interest in the association of obesity with AAA. Other pathogenic processes related to obesity, such as release of adipokines, add more complexity to the subject.59 Data on the association between measures of obesity and AAA are limited and inconsistent. A recent meta-analysis of cross-sectional studies found that 3 in 5 that examined body mass index (BMI) and 2 in 3 that examined waist circumference reported a positive association with presence of AAA.60 However, no causal relation can be inferred from these findings. There was no association between BMI and AAA growth based on limited data in 2 studies.60 In contrast, another recent meta-analysis reported an inverse relation between BMI and growth rate of small AAA, with each kg/m2 increase in BMI associated with a slower growth of AAA by 0.017 mm/y (p = 0.039) in an unadjusted model and 0.008 mm/y (p = 0.35) in an adjusted model.42

Majority of previous studies that have shown associations of obesity25,27,59,61,62 with AAA are cross-sectional. Only a few prospective studies have examined the association between obesity and incident AAA, the results are inconsistent. Out of eight studies that examined the associations of obesity with incident AAA, two20,34 reported a positive association for overall obesity (defined by BMI or body weight), six19,21,30,35,63,64 found no association for BMI but in two of them30,63 there was a positive association for abdominal obesity (defined by waist circumference or Sagittal abdominal diameter). These previous studies are generally limited in number of cases and method of case identification. In our recent prospective analysis in the Physicians’ Health Study, with 471 newly diagnosed AAA during a mean of 10.4 years’ follow-up, compared with men who had baseline BMI < 25 kg/m2, the multivariable HR (95% CI) of newly diagnosed AAA was 1.30 (1.06-1.59) for BMI 25-<30 kg/m2 and 1.69 (1.24–2.30) for BMI ≥ 30 kg/m2. The risk of diagnosed AAA was significantly higher by 6% with each unit increase in baseline BMI. This association was consistent regardless of the other known AAA risk factors and preexisting vascular diseases. Though it remains possible that other lifestyle factors correlated with obesity may explain this association, finding in mouse models that weight loss limited AAA progression lends support to a direct effect of obesity on AAA.65 Among several plausible pathogenic processes proposed to explain an association between obesity and AAA, the most compelling hypothesis is obesity-induced release of adipokines and aortic inflammation.17,66 The abdominal aorta is surrounded by significant amounts of peri-vascular adipose tissue. These adipose tissues produce and release various adipokines such as adiponectin,67 leptin,68 and resistin,69 that can modulate inflammation. In obesity, the release of pro-inflammatory adipokines by excessive peri-aortic adipose tissues will promote aortic inflammation, which leads to vessel weakening and dilatation.70-72 Histological study has shown that perivascular adipose tissue is in close proximity to vascular walls and release adipokines in high concentrations to the periabdominal aortic zone.73 Increased macrophage infiltration and inflammatory cytokine expression in peri-aortic adipose tissue had been found in mice with AAA.74 In a case-control study of 35 AAA patients and 140 age- and sex-matched controls, high-sensitivity C-reactive protein (hsCRP) level was significantly associated with AAA (odds ratio [OR] per 1 mg/L: 1.1, 95% CI: 1.01-1.2).75 In a population-based cohort study, serum concentrations of resistin (OR per 10 ng/mL: 1.53, 95% CI: 1.26-1.85) and adiponectin (OR per 5 μg/mL: 1.26, 95% CI: 1.07-1.50), but not leptin, were independently associated with the presence of AAA ≥ 30 mm, after controlling for other known risk factors.59

Implication for Future Research

The seemingly paradoxical inverse and positive associations of diabetes and obesity, respectively, with AAA has important clinical and public health implications. Although AAA is more common in individuals with atherosclerosis such as coronary artery disease, ample evidence suggests that the pathogenesis of AAA is different from that of occlusive atherosclerotic disease.76 Recent prospective evidence has also confirmed the contrasting associations of obesity and diabetes with AAA. Insights into the relation between diabetes, obesity and AAA will help identify high-risk subpopulations for AAA screening and optimize prevention strategy for individual patients. An improved knowledge of the mechanisms underlying the link between diabetes, obesity and AAA also has important therapeutic implications. For example, if hyperglycemia in diabetes contributes to the lower risk of AAA, the intensive blood glucose-lowering therapy may actually increase the risk of AAA in diabetic patients. On the other hand, if obesity-induced inflammation is the reason for the association between obesity and AAA, the pro-inflammatory adipokines may be a target for therapeutic intervention. Given the high prevalence of diabetes and obesity and the high mortality associated with AAA rupture, the relation between these health conditions is an urgent, unsettled research area that warrants further investigation.

Conclusions

AAA is a significant cause of morbidity and mortality in aging populations. Multiple risk factors for atherosclerosis are also risk factors of AAA. Accumulating evidence from epidemiological studies, especially prospective cohorts, suggest that baseline obesity is associated with a higher risk of clinically diagnosed AAA while a history of diabetes might be associated with a lower risk of diagnosed AAA. The complex associations of diabetes and obesity with risk of AAA highlight a unique pathogenesis of AAA with important clinical and public health implications.

References


  1. Svensjo S, Bjorck M, Gurtelschmid M, et al. Low prevalence of abdominal aortic aneurysm among 65-year-old Swedish men indicates a change in the epidemiology of the disease. Circulation. 2011;124: 1118-1123.
    [CROSSREF]
  2. McCarthy RJ, Shaw E, Whyman MR, et al. Recommendations for screening intervals for small aortic aneurysms. Br J Surg. 2003;90:821-826.
    [CROSSREF]
  3. Pfeifer M, Begerow B, Minne HW, et al. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001;86:1633-1637.
  4. Simoni G, Pastorino C, Perrone R, et al. Screening for abdominal aortic aneurysms and associated risk factors in a general population. Eur J Vasc Endovasc Surg. 1995;10:207-210.
    [CROSSREF]
  5. Newman AB, Arnold AM, Burke GL, et al. Cardiovascular disease and mortality in older adults with small abdominal aortic aneurysms detected by ultrasonography: the cardiovascular health study. Ann Intern Med. 2001;134:182-190.
    [CROSSREF]
  6. Le MT, Jamrozik K, Davis TM, et al. Negative association between infra-renal aortic diameter and glycaemia: the Health in Men Study. Eur J Vasc Endovasc Surg. 2007;33:599-604.
    [CROSSREF]
  7. Scott RA, Bridgewater SG, Ashton HA. Randomized clinical trial of screening for abdominal aortic aneurysm in women. Br J Surg. 2002;89:283-285.
    [CROSSREF]
  8. Bown MJ, Cooper NJ, Sutton AJ, et al. The post-operative mortality of ruptured abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg. 2004;27:65-74.
    [CROSSREF]
  9. Acosta S, Ogren M, Bengtsson H, et al. Increasing incidence of ruptured abdominal aortic aneurysm: a population-based study. J Vasc Surg. 2006;44:237-243.
    [CROSSREF]
  10. Darling RC, Messina CR, Brewster DC, et al. Autopsy study of unoperated abdominal aortic aneurysms. The case for early resection. Circulation. 1977;56:II161-II164.
  11. Ornish D. Comparison of diets for weight loss and heart disease risk reduction. JAMA. 2005;293:1589-1590.
  12. Sakalihasan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet. 2005;365:1577-1589.
    [CROSSREF]
  13. Schermerhorn M. A 66-year-old man with an abdominal aortic aneurysm: review of screening and treatment. JAMA. 2009;302:2015-2022.
    [CROSSREF]
  14. Lederle FA, Wilson SE, Johnson GR, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002;346:1437-1444.
    [CROSSREF]
  15. Lawrence PF, Gazak C, Bhirangi L, et al. The epidemiology of surgically repaired aneurysms in the United States. J Vasc Surg. 1999;30:632-640.
    [CROSSREF]
  16. EVAR trial participants. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet. 2005;365:2179-2186.
    [CROSSREF]
  17. Nordon IM, Hinchliffe RJ, Holt PJ, et al. Review of current theories for abdominal aortic aneurysm pathogenesis. Vascular. 2009;17:253-263.
    [CROSSREF]
  18. Ramiro E, Franch A, Castellote C, et al. Effect of Theobroma cacao flavonoids on immune activation of a lymphoid cell line. Br J Nutr. 2005;93:859-866.
    [CROSSREF]
  19. Reed D, Reed C, Stemmermann G, et al. Are aortic aneurysms caused by atherosclerosis? Circulation. 1992;85:205-211.
    [CROSSREF]
  20. Wong DR, Willett WC, Rimm EB. Smoking, hypertension, alcohol consumption, and risk of abdominal aortic aneurysm in men. Am J Epidemiol. 2007;165:838-845.
    [CROSSREF]
  21. Lederle FA, Larson JC, Margolis KL, et al. Abdominal aortic aneurysm events in the women’s health initiative: cohort study. BMJ. 2008;337:a1724.
    [CROSSREF]
  22. Lederle FA, Johnson GR, Wilson SE, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med. 1997;126:441-449.
    [CROSSREF]
  23. Smith FC, Grimshaw GM, Paterson IS, et al. Ultrasonographic screening for abdominal aortic aneurysm in an urban community. Br J Surg. 1993;80:1406-1409.
    [CROSSREF]
  24. Pleumeekers HJ, Hoes AW, van der Does E, et al. Aneurysms of the abdominal aorta in older adults. The Rotterdam Study. Am J Epidemiol. 1995;142:1291-1299.
    [CROSSREF]
  25. Lederle FA, Johnson GR, Wilson SE, et al. The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med. 2000;160:1425-1430.
    [CROSSREF]
  26. Kanagasabay R, Gajraj H, Pointon L, et al. Co-morbidity in patients with abdominal aortic aneurysm. J Med Screen. 1996;3:208-210.
    [CROSSREF]
  27. Kent KC, Zwolak RM, Egorova NN, et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg. 2010;52:539-548.
    [CROSSREF]
  28. Tornwall ME, Virtamo J, Haukka JK, et al. Life-style factors and risk for abdominal aortic aneurysm in a cohort of Finnish male smokers. Epidemiology. 2001;12:94-100.
    [CROSSREF]
  29. Rodin MB, Daviglus ML, Wong GC, et al. Middle age cardiovascular risk factors and abdominal aortic aneurysm in older age. Hypertension. 2003;42:61-68.
    [CROSSREF]
  30. Iribarren C, Darbinian JA, Go AS, et al. Traditional and novel risk factors for clinically diagnosed abdominal aortic aneurysm: the Kaiser multiphasic health checkup cohort study. Ann Epidemiol. 2007;17:669-678.
    [CROSSREF]
  31. Baumgartner I, Hirsch AT, Abola MT, et al. Cardiovascular risk profile and outcome of patients with abdominal aortic aneurysm in out-patients with atherothrombosis: data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. J Vasc Surg. 2008;48:808-814.
    [CROSSREF]
  32. Blanchard JF, Armenian HK, Friesen PP. Risk factors for abdominal aortic aneurysm: results of a case-control study. Am J Epidemiol. 2000;151:575-583.
    [CROSSREF]
  33. Shteinberg D, Halak M, Shapiro S, et al. Abdominal aortic aneurysm and aortic occlusive disease: a comparison of risk factors and inflammatory response. Eur J Vasc Endovasc Surg. 2000;20:462-465.
    [CROSSREF]
  34. Strachan DP. Predictors of death from aortic aneurysm among middle-aged men: the Whitehall study. Br J Surg. 1991;78:401-404.
    [CROSSREF]
  35. Forsdahl SH, Singh K, Solberg S, et al. Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the Tromso Study, 1994-2001. Circulation. 2009;119:2202-2208.
    [CROSSREF]
  36. Giacovelli JK, Egorova N, Nowygrod R, et al. Insurance status predicts access to care and outcomes of vascular disease. J Vasc Surg. 2008;48:905-911.
    [CROSSREF]
  37. Brady AR, Thompson SG, Fowkes FG, et al. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation. 2004;110:16-21.
    [CROSSREF]
  38. Vega de Ceniga M, Gomez R, Estallo L, et al. Growth rate and associated factors in small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2006;31:231-236.
    [CROSSREF]
  39. Golledge J, Karan M, Moran CS, et al. Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions. Eur Heart J. 2008;29:665-672.
    [CROSSREF]
  40. Ferguson CD, Clancy P, Bourke B, et al. Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J. 159:307-313.
    [CROSSREF]
  41. Thompson A, Cooper JA, Fabricius M, et al. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J Vasc Surg. 52:55-61 e2.
    [CROSSREF]
  42. Sweeting MJ, Thompson SG, Brown LC, et al. Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms. Br J Surg. 2012;99:655-665.
    [CROSSREF]
  43. Rensing KL, Twickler TB. Abdominal aorta aneurysm: an exceptional expression of atherosclerotic disease in type II diabetes. Eur Heart J. 2008;29:581-582.
    [CROSSREF]
  44. Dua MM, Miyama N, Azuma J, et al. Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic diameter in experimental aortic aneurysm disease. Surgery. 2010;148:429-435.
    [CROSSREF]
  45. Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005;48:1198-1206.
    [CROSSREF]
  46. Houard X, Rouzet F, Touat Z, et al. Topology of the fibrinolytic system within the mural thrombus of human abdominal aortic aneurysms. J Pathol. 2007;212:20-28.
    [CROSSREF]
  47. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006;26:987-994.
    [CROSSREF]
  48. Norman PE, Davis TM, Le MT, et al. Matrix biology of abdominal aortic aneurysms in diabetes: mechanisms underlying the negative association. Connect Tissue Res. 2007;48:125-131.
    [CROSSREF]
  49. Vorp DA. Biomechanics of abdominal aortic aneurysm. J Biomech. 2007;40:1887-1902.
    [CROSSREF]
  50. Mauer SM. Structural-functional correlations of diabetic nephropathy. Kidney Int. 1994;45:612-622.
    [CROSSREF]
  51. Astrand H, Ryden-Ahlgren A, Sundkvist G, et al. Reduced aortic wall stress in diabetes mellitus. Eur J Vasc Endovasc Surg. 2007;33:592-598.
    [CROSSREF]
  52. Schouten O, van Laanen JH, Boersma E, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg. 2006;32:21-26.
    [CROSSREF]
  53. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet. 2006;368:659-665.
    [CROSSREF]
  54. Li L, Mamputu JC, Wiernsperger N, et al. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes. 2005;54:2227-2234.
    [CROSSREF]
  55. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684.
    [CROSSREF]
  56. Miyama N, Dua MM, Yeung JJ, et al. Hyperglycemia limits experimental aortic aneurysm progression. J Vasc Surg. 2010;52:975-983.
    [CROSSREF]
  57. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307:491-497.
    [CROSSREF]
  58. Williams DE, Prevost AT, Whichelow MJ, et al. A cross-sectional study of dietary patterns with glucose intolerance and other features of the metabolic syndrome. Br J Nutr. 2000;83:257-266.
    [CROSSREF]
  59. Golledge J, Clancy P, Jamrozik K, et al. Obesity, adipokines, and abdominal aortic aneurysm: Health in Men study. Circulation. 2007;116:2275-2279.
    [CROSSREF]
  60. Cronin O, Walker PJ, Golledge J. The association of obesity with abdominal aortic aneurysm presence and growth. Atherosclerosis. 2012;226(2):321-327.
    [CROSSREF]
  61. Allison MA, Kwan K, DiTomasso D, et al. The epidemiology of abdominal aortic diameter. J Vasc Surg. 2008;48:121-127.
    [CROSSREF]
  62. Long A, Bui HT, Barbe C, et al. Prevalence of abdominal aortic aneurysm and large infrarenal aorta in patients with acute coronary syndrome and proven coronary stenosis: a prospective monocenter study. Ann Vasc Surg. 2010;24:602-608.
    [CROSSREF]
  63. Stackelberg O, Bjorck M, Sadr-Azodi O, et al. Obesity and abdominal aortic aneurysm. Br J Surg. 2012; 100(3):360-366.
    [CROSSREF]
  64. Lee AJ, Fowkes FG, Carson MN, et al. Smoking, atherosclerosis and risk of abdominal aortic aneurysm. Eur Heart J. 1997;18:671-676.
    [CROSSREF]
  65. Police SB, Putnam K, Thatcher S, et al. Weight loss in obese C57BL/6 mice limits adventitial expansion of established angiotensin II-induced abdominal aortic aneurysms. Am J Physiol Heart Circ Physiol. 2010;298:H1932-1938.
    [CROSSREF]
  66. Choke E, Cockerill G, Wilson WR, et al. A review of biological factors implicated in abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg. 2005;30:227-244.
    [CROSSREF]
  67. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473-2476.
    [CROSSREF]
  68. Shamsuzzaman AS, Winnicki M, Wolk R, et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation. 2004;109:2181-2185.
    [CROSSREF]
  69. Pang SS, Le YY. Role of resistin in inflammation and inflammation-related diseases. Cell Mol Immunol. 2006;3:29-34.
  70. Chatterjee TK, Stoll LL, Denning GM, et al. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res. 2009;104:541-549.
    [CROSSREF]
  71. Eringa EC, Bakker W, Smulders YM, et al. Regulation of vascular function and insulin sensitivity by adipose tissue: focus on perivascular adipose tissue. Microcirculation. 2007;14:389-402.
    [CROSSREF]
  72. Barandier C, Montani JP, Yang Z. Mature adipocytes and perivascular adipose tissue stimulate vascular smooth muscle cell proliferation: effects of aging and obesity. Am J Physiol Heart Circ Physiol. 2005;289: H1807-1813.
    [CROSSREF]
  73. Henrichot E, Juge-Aubry CE, Pernin A, et al. Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis? Arterioscler Thromb Vasc Biol. 2005;25:2594-2599.
    [CROSSREF]
  74. Police SB, Thatcher SE, Charnigo R, et al. Obesity promotes inflammation in periaortic adipose tissue and angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2009;29:14 58-1464.
    [CROSSREF]
  75. Wanhainen A, Bergqvist D, Boman K, et al. Risk factors associated with abdominal aortic aneurysm: a population-based study with historical and current data. J Vasc Surg. 2005;41:390-396.
    [CROSSREF]
  76. Golledge J, Norman PE. Atherosclerosis and abdominal aortic aneurysm: cause, response, or common risk factors? Arterioscler Thromb Vasc Biol. 2010;30:1075-1077.
    [CROSSREF]
XML PDF Share

FIGURES & TABLES

Figure 1.

Potential effects of diabetes on pathogenesis of abdominal aortic aneurysms.

Full Size   |   Slide (.pptx)

REFERENCES

  1. Svensjo S, Bjorck M, Gurtelschmid M, et al. Low prevalence of abdominal aortic aneurysm among 65-year-old Swedish men indicates a change in the epidemiology of the disease. Circulation. 2011;124: 1118-1123.
    [CROSSREF]
  2. McCarthy RJ, Shaw E, Whyman MR, et al. Recommendations for screening intervals for small aortic aneurysms. Br J Surg. 2003;90:821-826.
    [CROSSREF]
  3. Pfeifer M, Begerow B, Minne HW, et al. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001;86:1633-1637.
  4. Simoni G, Pastorino C, Perrone R, et al. Screening for abdominal aortic aneurysms and associated risk factors in a general population. Eur J Vasc Endovasc Surg. 1995;10:207-210.
    [CROSSREF]
  5. Newman AB, Arnold AM, Burke GL, et al. Cardiovascular disease and mortality in older adults with small abdominal aortic aneurysms detected by ultrasonography: the cardiovascular health study. Ann Intern Med. 2001;134:182-190.
    [CROSSREF]
  6. Le MT, Jamrozik K, Davis TM, et al. Negative association between infra-renal aortic diameter and glycaemia: the Health in Men Study. Eur J Vasc Endovasc Surg. 2007;33:599-604.
    [CROSSREF]
  7. Scott RA, Bridgewater SG, Ashton HA. Randomized clinical trial of screening for abdominal aortic aneurysm in women. Br J Surg. 2002;89:283-285.
    [CROSSREF]
  8. Bown MJ, Cooper NJ, Sutton AJ, et al. The post-operative mortality of ruptured abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg. 2004;27:65-74.
    [CROSSREF]
  9. Acosta S, Ogren M, Bengtsson H, et al. Increasing incidence of ruptured abdominal aortic aneurysm: a population-based study. J Vasc Surg. 2006;44:237-243.
    [CROSSREF]
  10. Darling RC, Messina CR, Brewster DC, et al. Autopsy study of unoperated abdominal aortic aneurysms. The case for early resection. Circulation. 1977;56:II161-II164.
  11. Ornish D. Comparison of diets for weight loss and heart disease risk reduction. JAMA. 2005;293:1589-1590.
  12. Sakalihasan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet. 2005;365:1577-1589.
    [CROSSREF]
  13. Schermerhorn M. A 66-year-old man with an abdominal aortic aneurysm: review of screening and treatment. JAMA. 2009;302:2015-2022.
    [CROSSREF]
  14. Lederle FA, Wilson SE, Johnson GR, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002;346:1437-1444.
    [CROSSREF]
  15. Lawrence PF, Gazak C, Bhirangi L, et al. The epidemiology of surgically repaired aneurysms in the United States. J Vasc Surg. 1999;30:632-640.
    [CROSSREF]
  16. EVAR trial participants. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet. 2005;365:2179-2186.
    [CROSSREF]
  17. Nordon IM, Hinchliffe RJ, Holt PJ, et al. Review of current theories for abdominal aortic aneurysm pathogenesis. Vascular. 2009;17:253-263.
    [CROSSREF]
  18. Ramiro E, Franch A, Castellote C, et al. Effect of Theobroma cacao flavonoids on immune activation of a lymphoid cell line. Br J Nutr. 2005;93:859-866.
    [CROSSREF]
  19. Reed D, Reed C, Stemmermann G, et al. Are aortic aneurysms caused by atherosclerosis? Circulation. 1992;85:205-211.
    [CROSSREF]
  20. Wong DR, Willett WC, Rimm EB. Smoking, hypertension, alcohol consumption, and risk of abdominal aortic aneurysm in men. Am J Epidemiol. 2007;165:838-845.
    [CROSSREF]
  21. Lederle FA, Larson JC, Margolis KL, et al. Abdominal aortic aneurysm events in the women’s health initiative: cohort study. BMJ. 2008;337:a1724.
    [CROSSREF]
  22. Lederle FA, Johnson GR, Wilson SE, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med. 1997;126:441-449.
    [CROSSREF]
  23. Smith FC, Grimshaw GM, Paterson IS, et al. Ultrasonographic screening for abdominal aortic aneurysm in an urban community. Br J Surg. 1993;80:1406-1409.
    [CROSSREF]
  24. Pleumeekers HJ, Hoes AW, van der Does E, et al. Aneurysms of the abdominal aorta in older adults. The Rotterdam Study. Am J Epidemiol. 1995;142:1291-1299.
    [CROSSREF]
  25. Lederle FA, Johnson GR, Wilson SE, et al. The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med. 2000;160:1425-1430.
    [CROSSREF]
  26. Kanagasabay R, Gajraj H, Pointon L, et al. Co-morbidity in patients with abdominal aortic aneurysm. J Med Screen. 1996;3:208-210.
    [CROSSREF]
  27. Kent KC, Zwolak RM, Egorova NN, et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg. 2010;52:539-548.
    [CROSSREF]
  28. Tornwall ME, Virtamo J, Haukka JK, et al. Life-style factors and risk for abdominal aortic aneurysm in a cohort of Finnish male smokers. Epidemiology. 2001;12:94-100.
    [CROSSREF]
  29. Rodin MB, Daviglus ML, Wong GC, et al. Middle age cardiovascular risk factors and abdominal aortic aneurysm in older age. Hypertension. 2003;42:61-68.
    [CROSSREF]
  30. Iribarren C, Darbinian JA, Go AS, et al. Traditional and novel risk factors for clinically diagnosed abdominal aortic aneurysm: the Kaiser multiphasic health checkup cohort study. Ann Epidemiol. 2007;17:669-678.
    [CROSSREF]
  31. Baumgartner I, Hirsch AT, Abola MT, et al. Cardiovascular risk profile and outcome of patients with abdominal aortic aneurysm in out-patients with atherothrombosis: data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. J Vasc Surg. 2008;48:808-814.
    [CROSSREF]
  32. Blanchard JF, Armenian HK, Friesen PP. Risk factors for abdominal aortic aneurysm: results of a case-control study. Am J Epidemiol. 2000;151:575-583.
    [CROSSREF]
  33. Shteinberg D, Halak M, Shapiro S, et al. Abdominal aortic aneurysm and aortic occlusive disease: a comparison of risk factors and inflammatory response. Eur J Vasc Endovasc Surg. 2000;20:462-465.
    [CROSSREF]
  34. Strachan DP. Predictors of death from aortic aneurysm among middle-aged men: the Whitehall study. Br J Surg. 1991;78:401-404.
    [CROSSREF]
  35. Forsdahl SH, Singh K, Solberg S, et al. Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the Tromso Study, 1994-2001. Circulation. 2009;119:2202-2208.
    [CROSSREF]
  36. Giacovelli JK, Egorova N, Nowygrod R, et al. Insurance status predicts access to care and outcomes of vascular disease. J Vasc Surg. 2008;48:905-911.
    [CROSSREF]
  37. Brady AR, Thompson SG, Fowkes FG, et al. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation. 2004;110:16-21.
    [CROSSREF]
  38. Vega de Ceniga M, Gomez R, Estallo L, et al. Growth rate and associated factors in small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2006;31:231-236.
    [CROSSREF]
  39. Golledge J, Karan M, Moran CS, et al. Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions. Eur Heart J. 2008;29:665-672.
    [CROSSREF]
  40. Ferguson CD, Clancy P, Bourke B, et al. Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J. 159:307-313.
    [CROSSREF]
  41. Thompson A, Cooper JA, Fabricius M, et al. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J Vasc Surg. 52:55-61 e2.
    [CROSSREF]
  42. Sweeting MJ, Thompson SG, Brown LC, et al. Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms. Br J Surg. 2012;99:655-665.
    [CROSSREF]
  43. Rensing KL, Twickler TB. Abdominal aorta aneurysm: an exceptional expression of atherosclerotic disease in type II diabetes. Eur Heart J. 2008;29:581-582.
    [CROSSREF]
  44. Dua MM, Miyama N, Azuma J, et al. Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic diameter in experimental aortic aneurysm disease. Surgery. 2010;148:429-435.
    [CROSSREF]
  45. Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005;48:1198-1206.
    [CROSSREF]
  46. Houard X, Rouzet F, Touat Z, et al. Topology of the fibrinolytic system within the mural thrombus of human abdominal aortic aneurysms. J Pathol. 2007;212:20-28.
    [CROSSREF]
  47. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006;26:987-994.
    [CROSSREF]
  48. Norman PE, Davis TM, Le MT, et al. Matrix biology of abdominal aortic aneurysms in diabetes: mechanisms underlying the negative association. Connect Tissue Res. 2007;48:125-131.
    [CROSSREF]
  49. Vorp DA. Biomechanics of abdominal aortic aneurysm. J Biomech. 2007;40:1887-1902.
    [CROSSREF]
  50. Mauer SM. Structural-functional correlations of diabetic nephropathy. Kidney Int. 1994;45:612-622.
    [CROSSREF]
  51. Astrand H, Ryden-Ahlgren A, Sundkvist G, et al. Reduced aortic wall stress in diabetes mellitus. Eur J Vasc Endovasc Surg. 2007;33:592-598.
    [CROSSREF]
  52. Schouten O, van Laanen JH, Boersma E, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg. 2006;32:21-26.
    [CROSSREF]
  53. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet. 2006;368:659-665.
    [CROSSREF]
  54. Li L, Mamputu JC, Wiernsperger N, et al. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes. 2005;54:2227-2234.
    [CROSSREF]
  55. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684.
    [CROSSREF]
  56. Miyama N, Dua MM, Yeung JJ, et al. Hyperglycemia limits experimental aortic aneurysm progression. J Vasc Surg. 2010;52:975-983.
    [CROSSREF]
  57. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307:491-497.
    [CROSSREF]
  58. Williams DE, Prevost AT, Whichelow MJ, et al. A cross-sectional study of dietary patterns with glucose intolerance and other features of the metabolic syndrome. Br J Nutr. 2000;83:257-266.
    [CROSSREF]
  59. Golledge J, Clancy P, Jamrozik K, et al. Obesity, adipokines, and abdominal aortic aneurysm: Health in Men study. Circulation. 2007;116:2275-2279.
    [CROSSREF]
  60. Cronin O, Walker PJ, Golledge J. The association of obesity with abdominal aortic aneurysm presence and growth. Atherosclerosis. 2012;226(2):321-327.
    [CROSSREF]
  61. Allison MA, Kwan K, DiTomasso D, et al. The epidemiology of abdominal aortic diameter. J Vasc Surg. 2008;48:121-127.
    [CROSSREF]
  62. Long A, Bui HT, Barbe C, et al. Prevalence of abdominal aortic aneurysm and large infrarenal aorta in patients with acute coronary syndrome and proven coronary stenosis: a prospective monocenter study. Ann Vasc Surg. 2010;24:602-608.
    [CROSSREF]
  63. Stackelberg O, Bjorck M, Sadr-Azodi O, et al. Obesity and abdominal aortic aneurysm. Br J Surg. 2012; 100(3):360-366.
    [CROSSREF]
  64. Lee AJ, Fowkes FG, Carson MN, et al. Smoking, atherosclerosis and risk of abdominal aortic aneurysm. Eur Heart J. 1997;18:671-676.
    [CROSSREF]
  65. Police SB, Putnam K, Thatcher S, et al. Weight loss in obese C57BL/6 mice limits adventitial expansion of established angiotensin II-induced abdominal aortic aneurysms. Am J Physiol Heart Circ Physiol. 2010;298:H1932-1938.
    [CROSSREF]
  66. Choke E, Cockerill G, Wilson WR, et al. A review of biological factors implicated in abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg. 2005;30:227-244.
    [CROSSREF]
  67. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473-2476.
    [CROSSREF]
  68. Shamsuzzaman AS, Winnicki M, Wolk R, et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation. 2004;109:2181-2185.
    [CROSSREF]
  69. Pang SS, Le YY. Role of resistin in inflammation and inflammation-related diseases. Cell Mol Immunol. 2006;3:29-34.
  70. Chatterjee TK, Stoll LL, Denning GM, et al. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res. 2009;104:541-549.
    [CROSSREF]
  71. Eringa EC, Bakker W, Smulders YM, et al. Regulation of vascular function and insulin sensitivity by adipose tissue: focus on perivascular adipose tissue. Microcirculation. 2007;14:389-402.
    [CROSSREF]
  72. Barandier C, Montani JP, Yang Z. Mature adipocytes and perivascular adipose tissue stimulate vascular smooth muscle cell proliferation: effects of aging and obesity. Am J Physiol Heart Circ Physiol. 2005;289: H1807-1813.
    [CROSSREF]
  73. Henrichot E, Juge-Aubry CE, Pernin A, et al. Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis? Arterioscler Thromb Vasc Biol. 2005;25:2594-2599.
    [CROSSREF]
  74. Police SB, Thatcher SE, Charnigo R, et al. Obesity promotes inflammation in periaortic adipose tissue and angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2009;29:14 58-1464.
    [CROSSREF]
  75. Wanhainen A, Bergqvist D, Boman K, et al. Risk factors associated with abdominal aortic aneurysm: a population-based study with historical and current data. J Vasc Surg. 2005;41:390-396.
    [CROSSREF]
  76. Golledge J, Norman PE. Atherosclerosis and abdominal aortic aneurysm: cause, response, or common risk factors? Arterioscler Thromb Vasc Biol. 2010;30:1075-1077.
    [CROSSREF]

EXTRA FILES

COMMENTS